An observational study in Metastatic Rectal Adenocarcinoma and Brain Metastases, sponsored by Aarhus University Hospital. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-03.
Sponsored by Aarhus University Hospital · Observational
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
In this study the investigators want to investigate the incidence of brain metastasis in a selected high-risk group of patients with metastatic colorectal cancer. Possible prognostic biological aspects will be investigated by translational analysis of biological samples. The study population consists of patients with metastatic rectal cancer and presence of lung metastasis. The patients will undergo a standard MRI scan of the brain including injection of intravenous contrast. If positive finding, images will be evaluated at the multidisciplinary tumor board for potential treatment options according to clinical practice. Standard follow-up program is followed, as per clinical practice. If the initial MRI scan of cerebrum detects brain metastasis this will be treated and followed as per clinical practice. Translational blood samples will be drawn at inclusion and at every imaging schedule up til 5 times
3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.
This study's planned enrollment of 50 is below the median of 121 across 594 observational studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Aarhus University Hospital is the lead sponsor of 289 studies on the registry; 79 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of patients with metastatic rectal cancer and presence of lung metastasis.
Primary rectal tumor location
Exclusion Criteria:
Incidence of brain metastasis
Incidence of brain metastasis in a high risk selected group
Time frame: 2 years
Number of brain metastases eligible for local treatment options
Number of brain metastases eligible for local treatment options
Time frame: 2 years
Median two year overall survival
Median two year overall survival
Time frame: 2 years last patient
Prognostic value of circulating DNA levels at baseline
Time frame: 2 years last patient
Descriptive biological analysis of tumor tissue and circulating tumor DNA
Time frame: 2 years last patient
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital